[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100556919":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":40,"centralContacts":41,"locations":40,"responsibleParty":51,"collaborators":40,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":40,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":40,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":75,"overallStatus":78,"whyStopped":40,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":40},{"fullName":5,"class":6},"Qianfoshan Hospital","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"\"Flumazenil group 1（F1 group）\"+\"Flumazenil group 2（F2 group）\"","ACTIVE_COMPARATOR","\"Flumazenil group 1（F1）\":Immediately after surgery, 0.5 mg flumazenil was administered, followed by an equal volume of saline (equal to the volume of 0.3 mg flumazenil) 25 minutes later.\n\n\"Flumazenil group 2（F2）\":Immediately after surgery, 0.5 mg flumazenil was administered, followed by 0.3 mg flumazenil 25 minutes later.",[13,14],"Drug: Flumazenil Injection（F1 group）","Drug: Flumazenil Injection（F2 group）",{"label":16,"type":17,"description":18,"interventionNames":19},"Control Group (C group)","PLACEBO_COMPARATOR","Immediately after surgery, an equal volume of saline (equal to the volume of 0.5 mg flumazenil) was administered, followed by an equal volume of saline (equal to the volume of 0.3 mg flumazenil) 25 minutes later.",[20],"Drug: Saline（C group）",[22,29,34],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","Flumazenil Injection（F1 group）","Flumazenil Injection（F1 group）: Immediately after surgery, 0.5 mg flumazenil was administered, followed by an equal volume of saline (equal to the volume of 0.3 mg flumazenil) 25 minutes later.",[9],[28],"Flumazenil at Different Dosages",{"type":23,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"Flumazenil Injection（F2 group）","Flumazenil Injection（F2 group）: Immediately after surgery, 0.5 mg flumazenil was administered, followed by 0.3 mg flumazenil 25 minutes later.",[9],[28],{"type":23,"name":35,"description":36,"armGroupLabels":37,"otherNames":38},"Saline（C group）","Flumazenil Injection（F2 group）: Immediately after surgery, an equal volume of saline (equal to the volume of 0.5 mg flumazenil) was administered, followed by an equal volume of saline (equal to the volume of 0.3 mg flumazenil) 25 minutes later.",[16],[39],"control group",null,[42,47],{"name":43,"role":44,"phone":45,"phoneExt":40,"email":46},"Guanghan Wu, Attending physician","CONTACT","18763995357","GuanghanWu2021@163.com",{"name":48,"role":44,"phone":49,"phoneExt":40,"email":50},"Jianbo Wu","13805319310","jianbowu@126.com",{"type":52,"investigatorFullName":48,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":40,"oldOrganization":40},"PRINCIPAL_INVESTIGATOR","Chief Physician","100556919","phase-1-flumazenil-antagonism-of-remimazolam-in-kidney-transplant-patients-100556919",false,"NCT06531369","Flumazenil Antagonism of Remimazolam in Kidney Transplant Patients","Application of Flumazenil to Antagonize Remimazolam and Evaluation of Remimazolam Plasma Concentration in Kidney Transplant Patients: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age ≥ 18 years and \\\u003C 65 years\n* Patients undergoing elective kidney transplant surgery\n* Signed the informed consent for the clinical study\n\nExclusion Criteria:\n\n* Liver decompensation (Child B\u002FC)\n* History of liver transplant\n* Previous allergies or other serious adverse reactions to narcotic drugs\n* Intraoperative depth monitoring of anesthesia is not expected\n* Preoperative ASA rating of 5\n* Received general anesthesia in the 30 days prior to surgery or plan to receive it again within 30 days\n* Plan to extend airway protection or mechanical ventilation support time after surgery\n* Previous participation in this study","ALL","18 Years","65 Years",{"count":65,"type":66},60,"ESTIMATED","INTERVENTIONAL",[69],"PHASE1","To investigate the effect of different doses of flumazenil antagonism on remimazolam plasma concentration in patients undergoing renal transplantation under general anesthesia.",[72,73,74],"Flumazenil to Antagonize Remimazolam","Remimazolam","Renal Transplantation",[76,73,77],"Flumazenil","renal transplantation","NOT_YET_RECRUITING","2024-07-30",{"date":81,"type":82},"2024-08-01","ACTUAL",{"date":84,"type":66},"2024-07",{"date":86,"type":66},"2026-03",{"name":5,"class":6}]